» Articles » PMID: 36307837

Short-term Efficacy and Adverse Effects of Collagenase Clostridium Histolyticum Injections, Percutaneous Needle Fasciotomy and Limited Fasciectomy in the Treatment of Dupuytren's Contracture: a Network Meta-analysis of Randomized Controlled Trials

Overview
Publisher Biomed Central
Specialties Orthopedics
Physiology
Date 2022 Oct 29
PMID 36307837
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Dupuytren's contracture (DC) is a chronic debilitating fibroproliferative disorder. Common treatment options include collagenase clostridium histolyticum injections (CI), percutaneous needle fasciotomy (NF) and limited fasciectomy (LF). Superiority of one specific treatment remains controversial. This study aims to assess the short-term efficacy and safety of CI, NF, and LF for the treatment of DC.

Methods: We included randomized controlled trials of CI compared with placebo, NF and LF for patients with DC. PubMed, Embase and the Cochrane Library were searched from inception to August 2021. Contracture reduction rates in treated joints (within 0-5° of full extension within 30 days), relative reduction in total passive extension deficit (TPED), occurrence of one or more adverse events and number of treatment-related adverse events per patient were the outcomes of interest. The Cochrane risk-of-bias tool was employed for quality assessment of the studies. A network meta-analysis was performed using MetaXL.

Results: Nine studies met our inclusion criteria (n = 903). Overall, risk bias was mixed and mostly low. Short term TPED reduction achieved with LF was superior compared to CI and NF. Although CI achieved greater TPED reduction compared to NF, it was associated with the highest risk of overall adverse effects. The analyzed data was limited to a maximum three-year follow-up period and therefore insufficient for long-term outcome evaluation.

Conclusions: In DC, LF may be able to provide patients with severe disease, superior flexion contracture release postoperatively. CI is a valid treatment alternative to NF, however the higher risk of overall adverse effects must be considered. The quality-of-evidence is limited due to short-term follow-up periods and a lack of standardized definitions of complications and adverse events.

Citing Articles

Therapy for Dupuytren's Disease (II): Collagenase Therapy vs. Limited Fasciectomy-A Long-Term Comparative Study.

Wachtel N, Dingler F, Kuhlmann C, Mert S, Haas-Lutzenberger E, Alt V Life (Basel). 2025; 15(1).

PMID: 39860016 PMC: 11767046. DOI: 10.3390/life15010076.


Bias in published randomized trials that compare collagenase injection with percutaneous needle fasciotomy in the treatment of Dupuytren disease: a systematic review.

Eckerdal D, Pakosta H, Ali M, Atroshi I EFORT Open Rev. 2024; 9(7):625-631.

PMID: 38949161 PMC: 11297408. DOI: 10.1530/EOR-23-0211.


Comparing Collagenase and Tissue Subcision for Cellulite Treatment of the Buttock and Thigh Regions: A Systematic Review and Meta-analysis.

Foppiani J, Raska O, Galinaud C, Stearns S, Hernandez Alvarez A, Taritsa I Plast Reconstr Surg Glob Open. 2024; 12(6):e5857.

PMID: 38911581 PMC: 11191026. DOI: 10.1097/GOX.0000000000005857.


Patient-Reported Outcome in Dupuytren's Disease Treated With Fasciectomy, Collagenase or Needle Fasciotomy: A Swedish Registry Study.

Harryson M, Eklund M, Arner M, Wilbrand S J Hand Surg Glob Online. 2023; 5(6):733-739.

PMID: 38106934 PMC: 10721495. DOI: 10.1016/j.jhsg.2023.06.009.


The biotechnological potential of proteases from hematophagous arthropod vectors.

de Araujo C, Santiago P, Causin Vieira G, Silva G, Moura R, Bastos I Front Cell Infect Microbiol. 2023; 13:1287492.

PMID: 37965257 PMC: 10641018. DOI: 10.3389/fcimb.2023.1287492.


References
1.
Sanjuan-Cervero R, Carrera-Hueso F, Vazquez-Ferreiro P, Ramon-Barrios M . Efficacy and adverse effects of collagenase use in the treatment of Dupuytren's disease: a meta-analysis. Bone Joint J. 2018; 100-B(1):73-80. DOI: 10.1302/0301-620X.100B1.BJJ-2017-0463.R1. View

2.
Zhou C, Hovius S, Slijper H, Feitz R, van Nieuwenhoven C, Pieters A . Collagenase Clostridium Histolyticum versus Limited Fasciectomy for Dupuytren's Contracture: Outcomes from a Multicenter Propensity Score Matched Study. Plast Reconstr Surg. 2015; 136(1):87-97. DOI: 10.1097/PRS.0000000000001320. View

3.
Abe Y . Comparison of Treatment Outcomes after Collagenase Injection and Percutaneous Needle Fasciotomy for Dupuytren's Contracture: Objective and Subjective Comparisons with a 3-Year Follow-Up. Plast Reconstr Surg. 2020; 145(6):1464-1474. DOI: 10.1097/PRS.0000000000006828. View

4.
Salari N, Heydari M, Hassanabadi M, Kazeminia M, Farshchian N, Niaparast M . The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020; 15(1):495. PMC: 7594412. DOI: 10.1186/s13018-020-01999-7. View

5.
Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N . Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am. 2010; 35(12):2027-38.e1. DOI: 10.1016/j.jhsa.2010.08.007. View